• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于泡腾和溶胀的盐酸二甲双胍缓释漂浮片的设计与体外评价

Design and In-vitro Evaluation of Sustained Release Floating Tablets of Metformin HCl Based on Effervescence and Swelling.

作者信息

Senjoti Faria Gias, Mahmood Syed, Jaffri Juliana Md, Mandal Uttam Kumar

机构信息

Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Malaysia.

出版信息

Iran J Pharm Res. 2016 Winter;15(1):53-70.

PMID:27610147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4986121/
Abstract

An oral sustained-release floating tablet formulation of metformin HCl was designed and developed. Effervescence and swelling properties were attributed on the developed tablets by sodium bicarbonate and HPMC-PEO polymer combination, respectively. Tablet composition was optimized by response surface methodology (RSM). Seventeen (17) trial formulations were analyzed according to Box-Behnken design of experiment where polymer content of HPMC and PEO at 1: 4 ratio (A), amount of sodium bi-carbonate (B), and amount of SSG (C) were adopted as independent variables. Floating lag time in sec (Y1), cumulative percent drug released at 1 h (Y2) and 12 h (Y3) were chosen as response variables. Tablets from the optimized formulation were also stored at accelerated stability condition (40°C and 75% RH) for 3 months to assess their stability profile. RSM could efficiently optimize the tablet composition with excellent prediction ability. In-vitro drug release until 12 h, floating lag time, and duration of floating were dependent on the amount of three selected independent variables. Optimized tablets remained floating for more than 24 h with a floating lag time of less than 4 min. Based on best fitting method, optimized formulation was found to follow Korsmeyer-Peppas release kinetic. Accelerated stability study revealed that optimized formulation was stable for three months without any major changes in assay, dissolution profile, floating lag time and other physical properties.

摘要

设计并开发了盐酸二甲双胍口服缓释漂浮片制剂。分别通过碳酸氢钠和羟丙甲纤维素-聚氧化乙烯聚合物组合赋予所开发片剂泡腾和膨胀特性。采用响应面法(RSM)对片剂组成进行优化。根据Box-Behnken实验设计分析了17种试验制剂,其中采用1:4比例的羟丙甲纤维素和聚氧化乙烯的聚合物含量(A)、碳酸氢钠用量(B)和羟丙基淀粉甘醇酸用量(C)作为自变量。选择以秒为单位的漂浮滞后时间(Y1)、1小时(Y2)和12小时(Y3)时的药物累积释放百分比作为响应变量。还将优化制剂的片剂在加速稳定性条件(40°C和75%相对湿度)下储存3个月,以评估其稳定性。响应面法能够有效地优化片剂组成,具有出色的预测能力。体外药物释放至12小时、漂浮滞后时间和漂浮持续时间取决于三个选定自变量的用量。优化后的片剂漂浮超过24小时,漂浮滞后时间小于4分钟。基于最佳拟合方法,发现优化制剂符合Korsmeyer-Peppas释放动力学。加速稳定性研究表明,优化制剂在三个月内稳定,含量测定、溶出曲线、漂浮滞后时间和其他物理性质均无重大变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/89b372211e6a/ijpr-15-053-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/f90ba9163135/ijpr-15-053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/d47df50323b0/ijpr-15-053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/9dde52bb809b/ijpr-15-053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/66cad2b329f7/ijpr-15-053-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/5878aab8c343/ijpr-15-053-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/4978100efeba/ijpr-15-053-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/bcf581f0e278/ijpr-15-053-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/89b372211e6a/ijpr-15-053-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/f90ba9163135/ijpr-15-053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/d47df50323b0/ijpr-15-053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/9dde52bb809b/ijpr-15-053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/66cad2b329f7/ijpr-15-053-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/5878aab8c343/ijpr-15-053-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/4978100efeba/ijpr-15-053-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/bcf581f0e278/ijpr-15-053-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1283/4986121/89b372211e6a/ijpr-15-053-g008.jpg

相似文献

1
Design and In-vitro Evaluation of Sustained Release Floating Tablets of Metformin HCl Based on Effervescence and Swelling.基于泡腾和溶胀的盐酸二甲双胍缓释漂浮片的设计与体外评价
Iran J Pharm Res. 2016 Winter;15(1):53-70.
2
Floating matrix tablets of domperidone formulation and optimization using simplex lattice design.多潘立酮漂浮型骨架片的处方设计与优化——采用单纯形格子设计法
Iran J Pharm Res. 2011 Summer;10(3):447-55.
3
Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride.盐酸雷尼替丁缓释漂浮型、生物黏附型和溶胀型基质片的设计、研制与优化。
PLoS One. 2021 Jun 25;16(6):e0253391. doi: 10.1371/journal.pone.0253391. eCollection 2021.
4
Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension.用于治疗高血压的胃滞留漂浮双层片的制剂与评价
Heliyon. 2020 Nov 13;6(11):e05459. doi: 10.1016/j.heliyon.2020.e05459. eCollection 2020 Nov.
5
Formulation and evaluation of different floating tablets containing metronidazole to target stomach.含甲硝唑的不同胃靶向漂浮片的制剂与评价
Curr Drug Deliv. 2015;12(4):425-43. doi: 10.2174/156720181204150729125655.
6
Effects of Formulation and Process Variables on Gastroretentive Floating Tablets with A High-Dose Soluble Drug and Experimental Design Approach.制剂和工艺变量对含高剂量可溶性药物的胃滞留漂浮片的影响及实验设计方法
Pharmaceutics. 2018 Sep 17;10(3):161. doi: 10.3390/pharmaceutics10030161.
7
Design, preparation, and evaluation of gastroretentive floating matrix tablet of mitiglinide.米格列奈胃内滞留漂浮型骨架片的设计、制备及评价
Front Pharmacol. 2023 Mar 15;14:1140351. doi: 10.3389/fphar.2023.1140351. eCollection 2023.
8
Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach.采用质量源于设计(QbD)方法研制盐酸尼卡地平胃滞留缓释片。
Drug Dev Ind Pharm. 2018 May;44(5):787-799. doi: 10.1080/03639045.2017.1413111. Epub 2017 Dec 18.
9
Formulation and in vitro evaluation of floating tablets of hydroxypropyl methylcellulose and polyethylene oxide using ranitidine hydrochloride as a model drug.以盐酸雷尼替丁为模型药物的羟丙基甲基纤维素和聚环氧乙烷胃漂浮片的制剂与体外评价
J Young Pharm. 2012 Oct;4(4):201-8. doi: 10.4103/0975-1483.104363.
10
Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet.甲磺酸伊马替尼泡腾漂浮缓释片的处方设计及体内外评价
PLoS One. 2015 Jun 2;10(6):e0126874. doi: 10.1371/journal.pone.0126874. eCollection 2015.

引用本文的文献

1
Novel Curcumin Floating Tablets for Spatial Delivery in Peptic Ulcer.用于消化性溃疡空间给药的新型姜黄素漂浮片
Biomed Res Int. 2025 Jul 23;2025:6622146. doi: 10.1155/bmri/6622146. eCollection 2025.
2
Current Developments in the Delivery of Gastro-Retentive Drugs.胃滞留型药物递送的当前进展
AAPS PharmSciTech. 2025 Feb 7;26(2):57. doi: 10.1208/s12249-025-03052-4.
3
An Overview of Microparticulate Drug Delivery System and its Extensive Therapeutic Applications in Diabetes.微颗粒药物递送系统概述及其在糖尿病中的广泛治疗应用

本文引用的文献

1
Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery.双功能胶囊剂型:新型扇形圆柱形克拉霉素胃滞留系统及盐酸雷尼替丁速释颗粒用于同步给药。
Int J Pharm. 2014 Jan 30;461(1-2):310-21. doi: 10.1016/j.ijpharm.2013.11.053. Epub 2013 Dec 3.
2
Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin: optimization and pharmacokinetics.评估微海绵作为姜黄素胃滞留型药物传递系统的可行性:优化和药代动力学。
Int J Pharm. 2014 Jan 2;460(1-2):1-12. doi: 10.1016/j.ijpharm.2013.10.045. Epub 2013 Nov 1.
3
Adv Pharm Bull. 2022 Aug;12(4):730-746. doi: 10.34172/apb.2022.075. Epub 2021 Oct 4.
4
DoE-Based Design of a Simple but Efficient Preparation Method for a Non-Effervescent Gastro-Retentive Floating Tablet Containing Metformin HCl.基于实验设计法的含盐酸二甲双胍的非泡腾胃滞留漂浮片简单高效制备方法的设计
Pharmaceutics. 2021 Aug 8;13(8):1225. doi: 10.3390/pharmaceutics13081225.
5
Development of Floating Tablets of Metformin HCl by Thermoplastic Granulation. Part II: Evaluation of the Combined Effect of Acacia Gum/HPMC on Biopharmaceutical Performances.通过热塑性制粒法制备盐酸二甲双胍漂浮片。第二部分:阿拉伯胶/羟丙基甲基纤维素对生物药剂学性能的联合作用评估。
Adv Pharm Bull. 2020 Jul;10(3):399-407. doi: 10.34172/apb.2020.048. Epub 2020 May 11.
Applications of poly(ethylene oxide) in controlled release tablet systems: a review.
聚环氧乙烷在控释片剂系统中的应用:综述
Drug Dev Ind Pharm. 2014 Jul;40(7):845-51. doi: 10.3109/03639045.2013.831438. Epub 2013 Sep 3.
4
Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia.每日一次胃滞留型剂型加巴喷丁治疗带状疱疹后神经痛的药代动力学、疗效和耐受性。
J Pharm Sci. 2013 Apr;102(4):1155-64. doi: 10.1002/jps.23467. Epub 2013 Feb 4.
5
Formulation, in vitro evaluation and study of variables on tri-layered gastro-retentive delivery system of diltiazem HCl.盐酸地尔硫䓬三层胃滞留型给药系统的制剂、体外评价及变量研究。
Drug Dev Ind Pharm. 2014 Mar;40(3):380-9. doi: 10.3109/03639045.2012.763138. Epub 2013 Feb 1.
6
Preparation of highly porous gastroretentive metformin tablets using a sublimation method.采用升华法制备高多孔胃滞留型二甲双胍片。
Eur J Pharm Biopharm. 2013 Apr;83(3):460-7. doi: 10.1016/j.ejpb.2012.11.009. Epub 2012 Dec 12.
7
Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies.通过胃滞留漂浮制剂提高巴氯芬的生物利用度:统计优化、体外和体内药代动力学研究。
Drug Dev Ind Pharm. 2013 Jun;39(6):880-8. doi: 10.3109/03639045.2012.709249. Epub 2012 Aug 20.
8
Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration.工业视角下的胃滞留型药物传递系统:物理化学、生物制药、技术和监管方面的考虑。
Expert Opin Drug Deliv. 2012 May;9(5):551-65. doi: 10.1517/17425247.2012.677431.
9
Development of gastroretentive drug delivery system for cefuroxime axetil: in vitro and in vivo evaluation in human volunteers.开发头孢呋辛酯的胃滞留给药系统:在人体志愿者中的体外和体内评价。
Pharm Dev Technol. 2013 Sep-Oct;18(5):1230-7. doi: 10.3109/10837450.2012.660698. Epub 2012 Feb 21.
10
Gastroretentive microballoons of metformin: Formulation development and characterization.二甲双胍胃滞留微球:制剂开发与表征
J Adv Pharm Technol Res. 2011 Jan;2(1):51-5. doi: 10.4103/2231-4040.79806.